Shalabh Gupta, MD

Shalabh Gupta, MD has a diverse work experience spanning multiple companies and roles. In 2010, they became a founding team member, advisor, and board member for various healthcare entrepreneurial startups in the Bay Area. Shalabh also founded BioCycive Inc., a company focused on oncology programs, which was later acquired by Sorrento Therapeutics for over $160MM.

In 2012, Gupta became an advisor for SPARK at Stanford University School of Medicine, supporting the process of discovering and testing potential new therapies. Shalabh also joined the Commercial Advisory Board at the University of Maryland Medical Center in 2011.

In 2013, Gupta became a Charter Member of TiE and a Member of Founders Network. Shalabh also founded and served as CEO of Globavir Biosciences, Inc., raising various rounds of financing.

In 2016, Gupta founded Unicycive Therapeutics and took the company public on NASDAQ in 2021. Additionally, they served on the Board of Directors for the Beall Center for Innovation and Entrepreneurship in 2018.

Recently, in 2021, Gupta became an advisor for UCSF Innovation Ventures. Throughout their career, Gupta has played key roles in founding and leading companies, advising startups, and supporting the advancement of innovative healthcare solutions.

Shalabh Gupta, MD, pursued their education with a focus on healthcare and medicine. Shalabh started their academic journey in 1998 at the NYU Robert F. Wagner Graduate School of Public Service, where they obtained a Master's in Public Administration (MPA), specializing in Health Care Finance and Management. Following this, they attended the NYU Grossman School of Medicine from 1999 to 2004, completing their Internship, Residency, and Fellowship in the fields of Internal Medicine, Physical Medicine & Rehabilitation, and Cardiac Rehabilitation.

In addition to their educational qualifications, Dr. Shalabh Gupta holds professional certifications. Shalabh is certified by the Medical Board of California, through the California State Medical Board. Furthermore, they have obtained certifications in Series 7, 63, 86, and 87, which are regulated by FINRA (Financial Industry Regulatory Authority).